Novartis AG
TGFbeta 2 antibodies
Last updated:
Abstract:
This invention is in the field of anti-transforming growth factor beta 2 (TGF-.beta.2) antibodies. In particular, the invention provides human monoclonal antibodies that bind the human TGF-.beta.2 isoform preferentially over the human TGF-.beta.1 or TGF-.beta.3 isoforms.
Status:
Grant
Type:
Utility
Filling date:
17 Feb 2017
Issue date:
23 Nov 2021